

IN THE CLAIMS:

The following listing replaces all prior versions of the claims:

1-9. (Canceled)

10. (Withdrawn) The method for screening substances promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 8, wherein the comparison/estimation with a wild-type non-human animal of its littermate is performed as a control when measuring/estimating response to mycobacterial lipoproteins/lipopeptides.

11. (Withdrawn) The method for screening substances promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 8, wherein the substance promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides is an agonist or an antagonist to TLR1.

12. (Withdrawn) The method for screening substances promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 8, wherein the substance promoting response to mycobacterial lipoproteins/lipopeptides is a therapeutic/preventive agent for mycobacterial infection.

13. (Withdrawn) The method for screening substances promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 12, wherein the mycobacterial infection is tuberculous or a mycobacterial infection other than tuberculous.

14. (Withdrawn) A substance promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides, obtained by the method for screening a substance promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 8.

15. (Withdrawn) The substance promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 14, wherein the substance promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides is an agonist or antagonist to TLR1.

16. (Withdrawn) The substance promoting or suppressing the response to mycobacterial lipoproteins/lipopeptides according to claim 14, wherein the substance promoting the response to mycobacterial lipoproteins/lipopeptides is a therapeutic/preventive agent for mycobacterial infection.

17-19. (Canceled)

20. (Currently amended) A transgenic mouse ~~wherein the~~ whose genome ~~of the mouse~~ comprises a homozygous inactivation of the Toll-like Receptor 1 (TLR1) gene; ~~the said~~ the TLR1 gene ~~encodes~~ encoding a polypeptide that recognizes triacylated mycobacterial lipoproteins; ~~wherein peritoneal macrophages of the mouse, also comprising a homozygous inactivation of the TLR1 gene,~~ exhibit decreased responsiveness to the triacylated mycobacterial lipoproteins; and the peritoneal macrophages also comprise a homozygous disruption of the TLR1 gene.

21. (Canceled)

22. (Withdrawn, currently amended) A method for screening substances promoting or suppressing a response to mycobacterial lipoproteins/lipopeptides, said method comprising contacting using cells derived from [[a]] the transgenic mouse of claim 20 with a test substance and a mycobacterial lipoprotein/lipopeptide and measuring the responsiveness of said cells to said mycobacterial lipoprotein/lipopeptide, wherein an increase in responsiveness to said mycobacterial lipoprotein/lipopeptide compared to a control is indicative of a substance that promotes a response to mycobacterial lipoprotein/lipopeptide, and a decrease in responsiveness to said mycobacterial lipoprotein/lipopeptide compared to a control is indicative of a substance that suppresses a response to mycobacterial lipoprotein/lipopeptide ~~as model cells non-responsive to triacylated mycobacterial lipoprotein or to synthetic triacylated lipopeptide, wherein the genome of the mouse comprises a homozygous inactivation of the Toll-like Receptor 1 (TLR1) gene; the TLR1 gene encodes a polypeptide that recognizes triacylated mycobacterial lipoproteins; peritoneal macrophages of the mouse exhibit decreased responsiveness to the triacylated mycobacterial lipoproteins; and the peritoneal macrophages also comprise a homozygous disruption of the TLR1 gene.~~

23. (Canceled)

24. (Withdrawn) The method according to claim 22, wherein Synthetic triacylated lipopeptide is N-palmitoyl-S-dilaurylglyceryl.

25. (New) The method according to claim 22, wherein said cells are immunocytes.

26. (New) The method according to claim 25, wherein said immunocytes are selected from the group consisting of macrophages, splenic cells and dendritic cells.